173 related articles for article (PubMed ID: 35111291)
1. Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Doni K; Bühn S; Weise A; Mann NK; Hess S; Sönnichsen A; Pieper D; Thürmann P; Mathes T
Ther Adv Drug Saf; 2022; 13():20420986211072383. PubMed ID: 35111291
[TBL] [Abstract][Full Text] [Related]
2. A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis.
Farah D; Leme GM; Eliaschewitz FG; Fonseca MCM
Diabetes Res Clin Pract; 2019 Mar; 149():47-63. PubMed ID: 30710655
[TBL] [Abstract][Full Text] [Related]
3. Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.
Zhang Y; Hong J; Chi J; Gu W; Ning G; Wang W
Diabetes Metab Res Rev; 2014 Mar; 30(3):241-56. PubMed ID: 24123720
[TBL] [Abstract][Full Text] [Related]
4. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing.
Schott G; Martinez YV; Ediriweera de Silva RE; Renom-Guiteras A; Vögele A; Reeves D; Kunnamo I; Marttila-Vaara M; Sönnichsen A
BMC Geriatr; 2017 Oct; 17(Suppl 1):226. PubMed ID: 29047372
[TBL] [Abstract][Full Text] [Related]
6. Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
Yang M; Wang L; Gu L; Yuan W
J Diabetes; 2017 Dec; 9(12):1107-1117. PubMed ID: 28266136
[TBL] [Abstract][Full Text] [Related]
7. The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
O'Hara DV; Parkhill TR; Badve SV; Jun M; Jardine MJ; Perkovic V
Diabetes Obes Metab; 2021 Mar; 23(3):763-773. PubMed ID: 33269512
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
Rehman MB; Tudrej BV; Soustre J; Buisson M; Archambault P; Pouchain D; Vaillant-Roussel H; Gueyffier F; Faillie JL; Perault-Pochat MC; Cornu C; Boussageon R
Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
[TBL] [Abstract][Full Text] [Related]
9. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Gooßen K; Gräber S
Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.
Volke V; Katus U; Johannson A; Toompere K; Heinla K; Rünkorg K; Uusküla A
BMC Endocr Disord; 2022 Oct; 22(1):251. PubMed ID: 36261824
[TBL] [Abstract][Full Text] [Related]
11. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a meta-analysis.
Chen Y; Men K; Li XF; Li J; Liu M; Fan ZQ
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3502-3514. PubMed ID: 29917205
[TBL] [Abstract][Full Text] [Related]
13. Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.
Li R; Wang R; Li H; Sun S; Zou M; Cheng G
Diabetes Metab Res Rev; 2016 Sep; 32(6):460-9. PubMed ID: 26433213
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
Foroutan N; Muratov S; Levine M
Clin Invest Med; 2016 Apr; 39(2):E48-62. PubMed ID: 27040861
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis.
Cheng D; Fei Y; Liu Y; Li J; Chen Y; Wang X; Wang N
PLoS One; 2014; 9(10):e111543. PubMed ID: 25360775
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials.
Walker SR; Komenda P; Khojah S; Al-Tuwaijri W; MacDonald K; Hiebert B; Tangri N; Nadurak SWD; Ferguson TW; Rigatto C; Tangri N
Nephron; 2017; 136(2):85-94. PubMed ID: 28178698
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
Kaneko M; Narukawa M
Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
